Farther Finance Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Farther Finance Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35	Hold	25	–	–	﹤0.01%	5874
2026 Q1	$31	Hold	25	–	–	﹤0.01%	5611
2025 Q4	$40	Buy	+25	New	+$52	﹤0.01%	5366
2025 Q2	–	Sell	-5	Closed	-$10	–	4521
2025 Q1	$10	Sell	5 -1	-17%	-$4	﹤0.01%	4219
2024 Q4	$36	Buy	+6	New	+$50	﹤0.01%	3892
2024 Q2	–	Sell	-5	Closed	-$231	–	3835
2024 Q1	$231	Buy	+5	New	+$239	﹤0.01%	3236

Other funds holding BTAI

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

Farther Finance Advisors's BTAI Position: Q2 2026 in Review

Farther Finance Advisors held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 25 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #5874.

Farther Finance Advisors first reported a position in BTAI in Q1 2024 and has held it in 6 quarters since. The position peaked at $231 in Q1 2024. 3 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Farther Finance Advisors held 25 shares of BioXcel Therapeutics worth $35 as of Q2 2026.
Farther Finance Advisors left its BioXcel Therapeutics share count unchanged in Q2 2026.
BioXcel Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5874 holding.
Farther Finance Advisors first reported a position in BioXcel Therapeutics in Q1 2024 and has held it in 6 quarters since.
Farther Finance Advisors's BioXcel Therapeutics position peaked at $231 in Q1 2024.
3 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.